A Knight is Reborn
Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, today announced that Samira Sakhia, former CFO of Paladin Labs Inc. ("Paladin"), will be joining the Knight team as President and member of the Board of Directors. In her new role, beginning on August 31, 2016, Samira will report to Jonathan Ross Goodman, CEO of Knight.
Ms. Sakhia served as the CFO at Paladin (acquired by Endo International plc February 2014), a specialty pharmaceutical company from 2001 to 2015. At Paladin, Ms. Sakhia was responsible for the finance, operations, human resources and investor relations functions. During her employment with Paladin, Ms. Sakhia was instrumental in executing in-licensing and acquisition transactions of Canadian and international pharmaceutical products and businesses. In addition, Ms. Sakhia led several M&A and strategic lending transactions as well as equity rounds on the TSX and completed the sale of Paladin to Endo International for over $3 billion. Ms. Sakhia holds an MBA and a Bachelors of Commerce degree from Ï㽶ÊÓƵ and is also a Chartered Professional Accountant.
Read full article: , August 17, 2016Â